Neurocrine (NBIX) director pre-plans sale of 3,810 shares via 10b5-1 plan

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk sold 3,810 shares of common stock in an open-market transaction at a weighted average price of $155.0134 per share. The trades were executed by a broker at prices ranging from $155.00 to $155.0550.

The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, which was adopted and made effective in advance and cannot be modified under issuer policy after adoption. Following this transaction, Norwalk directly holds 2,429 shares of Neurocrine Biosciences common stock.

Insider Trade Summary 10b5-1

Net Seller: 3,810 shares ($590,601)

Net Sell 1 txn

Insider Norwalk Leslie V

Role null

Sold 3,810 shs ($591K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,810	$155.0134	$591K

Holdings After Transaction: Common Stock — 2,429 shares (Direct, null)

Footnotes (1)

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.00 to $155.0550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Key Figures

Shares sold: 3,810 shares Weighted average sale price: $155.0134 per share Post-transaction holdings: 2,429 shares +2 more

5 metrics

Shares sold 3,810 shares Open-market sale of common stock on 2026-05-12

Weighted average sale price $155.0134 per share Average price across multiple sale transactions

Post-transaction holdings 2,429 shares Direct common stock ownership after the sale

Price range of sales $155.00–$155.0550 per share Range of execution prices in the reported transactions

Net shares sold 3,810 shares Net-sell direction from transaction summary

Key Terms

Rule 10b5-1 trading plan, weighted average sales price per share, open-market sale, disposition

4 terms

Rule 10b5-1 trading plan financial

"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sales price per share financial

"Represents a weighted average sales price per share. These shares were sold in multiple transactions"

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

disposition financial

"The disposition reported in this Form 4 was effected by a broker pursuant to instructions"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Norwalk Leslie V

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/12/2026		S(1)		3,810	D	$155.0134(2)	2,429	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.00 to $155.0550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did NBIX director Leslie V. Norwalk report?

Leslie V. Norwalk reported selling 3,810 shares of Neurocrine Biosciences common stock in an open-market transaction. The trade was executed through a broker under a pre-arranged Rule 10b5-1 trading plan at prices around $155 per share.

At what price did NBIX shares sell in Leslie Norwalk’s Form 4 filing?

The reported sale used a weighted average price of $155.0134 per NBIX share. Individual trades occurred in multiple transactions at prices ranging from $155.00 to $155.0550, all executed by a broker under Norwalk’s Rule 10b5-1 trading plan.

How many NBIX shares does Leslie Norwalk hold after this transaction?

After the reported sale, Leslie V. Norwalk directly holds 2,429 shares of Neurocrine Biosciences common stock. This figure reflects her direct ownership position immediately following the 3,810-share open-market sale disclosed in the Form 4 filing.

Was Leslie Norwalk’s NBIX stock sale pre-planned under Rule 10b5-1?

Yes. The Form 4 states the disposition was effected by a broker under a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Company policy restricts her from amending or modifying the plan after adoption, indicating a pre-scheduled trading program.

What does the weighted average sales price mean in the NBIX Form 4?

The weighted average price of $155.0134 reflects multiple NBIX share sales at slightly different prices. According to the filing, trades occurred between $155.00 and $155.0550, and detailed breakdowns by price level are available from the issuer, security holders, or SEC staff on request.